PubMed

Intensification of oxidative stress and inflammation in type 2 diabetes despite antihyperglycemic treatment.

Farah R, Shurtz-Swirski R, Lapin O.

Cardiovasc Diabetol. 2008 Jun 22;7:20.PMID: 18570678 [PubMed - indexed for MEDLINE]Free PMC ArticleFree textRelated citations

Primed polymorphonuclear leukocytes constitute a possible link between inflammation and oxidative stress in hyperlipidemic patients.

Mazor R, Shurtz-Swirski R, Farah R, Kristal B, Shapiro G, Dorlechter F, Cohen-Mazor M, Meilin E, Tamara S, Sela S.

Atherosclerosis. 2008 Apr;197(2):937-43. Epub 2007 Sep 17.PMID: 17869258 [PubMed - indexed for MEDLINE]Related citations

Oxidative stress and inflammation due to peripheral polymorphonuclear leukocytes after coronary angiography vs percutaneous coronary intervention.

Farah R, Shurtz-Swirski R, Bolotin Y, Brezins M.

Minerva Cardioangiol. 2008 Apr;56(2):189-95.PMID: 18319697 [PubMed - indexed for MEDLINE]Related citations

Primed polymorphonuclear leukocytes constitute a possible link between inflammation and oxidative stress in hyperlipidemic patients: effect of statins.

Farah R, Shurtz-Swirski R, Dorlechter F.

Minerva Cardioangiol. 2010 Apr;58(2):175-81.PMID: 20440247 [PubMed - in process]Related citations

The combined effect of calcium channel blocker Lercanidipine and antioxidants on low-grade systemic inflammation parameters in essential hypertension patients.

Farah R, Shurtz-Swirski R.

Minerva Cardioangiol. 2008 Oct;56(5):467-76.PMID: 18813182 [PubMed - indexed for MEDLINE]Related citations

Thiazolidinediones increase hepatic insulin extraction in African Americans with impaired glucose tolerance and type 2 diabetes mellitus. A pilot study of rosiglitazone.

Osei K, Gaillard T, Schuster D.

Metabolism. 2007 Jan;56(1):24-9.PMID: 17161222 [PubMed - indexed for MEDLINE]Related citations

Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus.

Kelly AS, Thelen AM, Kaiser DR, Gonzalez-Campoy JM, Bank AJ.

Vasc Med. 2007 Nov;12(4):311-8.PMID: 18048467 [PubMed - indexed for MEDLINE]Related citations

Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease.

Sela S, Shurtz-Swirski R, Cohen-Mazor M, Mazor R, Chezar J, Shapiro G, Hassan K, Shkolnik G, Geron R, Kristal B.

J Am Soc Nephrol. 2005 Aug;16(8):2431-8. Epub 2005 Jun 29. Erratum in: J Am Soc Nephrol. 2005 Sep;16(9):2814. PMID: 15987755 [PubMed - indexed for MEDLINE]Free ArticleRelated citations

[The effect of calcium channel blocker lercanidipine on lowgrade inflammation parameters in essential hypertension patients]

Shurtz-Swirski R, Farah R, Sela S, Shapiro G, Klempef R, Snitkovski T, Kristal B.

Harefuah. 2006 Dec;145(12):895-9, 942. Hebrew. PMID: 17220028 [PubMed - indexed for MEDLINE]Related citations

A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes.

Stocker DJ, Taylor AJ, Langley RW, Jezior MR, Vigersky RA.

Am Heart J. 2007 Mar;153(3):445.e1-6.PMID: 17307426 [PubMed - indexed for MEDLINE]Related citations

Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with type 2 diabetes mellitus.

Sahin M, Tutuncu NB, Ertugrul D, Tanaci N, Guvener ND.

J Diabetes Complications. 2007 Mar-Apr;21(2):118-23.PMID: 17331860 [PubMed - indexed for MEDLINE]Related citations

Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes.

Yilmaz H, Gursoy A, Sahin M, Guvener Demirag N.

Acta Diabetol. 2007 Dec;44(4):187-92. Epub 2007 Aug 29.PMID: 17726570 [PubMed - indexed for MEDLINE]Related citations

Beta-cell response to intravenous glucagon in African-American and Hispanic children with type 2 diabetes mellitus.

Taha DR, Castells S, Umpaichitra V, Bastian W, Banerji MA.

J Pediatr Endocrinol Metab. 2002 Jan;15(1):59-67.PMID: 11822582 [PubMed - indexed for MEDLINE]Related citations

Competact, a fixed combination of pioglitazone and metformin, improves metabolic markers in type 2 diabetes patients with insufficient glycemic control by metformin alone--results from a post-marketing surveillance trial under daily routine conditions.

Schöndorf T, Karagiannis E, Posseldt RE, Forst T, Pfützner A.

Diabetes Technol Ther. 2009 Jun;11(6):379-83.PMID: 19459767 [PubMed - indexed for MEDLINE]Related citations

A randomized, controlled trial of the effects of rosiglitazone on adipokines, and inflammatory and fibrinolytic markers in diabetic patients: study design and protocol.

Gupta M, Braga MB, Verma S.

Can J Cardiol. 2008 Oct;24(10):e65-9.PMID: 18841263 [PubMed - indexed for MEDLINE]Free PMC ArticleFree textRelated citations

Decrease in serum C-reactive protein levels by troglitazone is associated with pretreatment insulin resistance, but independent of its effect on glycemia, in type 2 diabetic subjects.

Yatagai T, Nakamura T, Nagasaka S, Kusaka I, Ishikawa SE, Yoshitaka A, Ishibashi S.

Diabetes Res Clin Pract. 2004 Jan;63(1):19-26.PMID: 14693409 [PubMed - indexed for MEDLINE]Related citations

Impact of rosiglitazone and glyburide on nitrosative stress and myocardial blood flow regulation in type 2 diabetes mellitus.

Pop-Busui R, Oral E, Raffel D, Byun J, Bajirovic V, Vivekanandan-Giri A, Kellogg A, Pennathur S, Stevens MJ.

Metabolism. 2009 Jul;58(7):989-94.PMID: 19394661 [PubMed - indexed for MEDLINE]Related citations

Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial.

Pradhan AD, Everett BM, Cook NR, Rifai N, Ridker PM.

JAMA. 2009 Sep 16;302(11):1186-94.PMID: 19755697 [PubMed - indexed for MEDLINE]Free ArticleRelated citations

Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT).

Kahn SE, Haffner SM, Viberti G, Herman WH, Lachin JM, Kravitz BG, Yu D, Paul G, Holman RR, Zinman B; Diabetes Outcome Progression Trial (ADOPT) Study Group.

Diabetes Care. 2010 Jan;33(1):177-83. Epub 2009 Oct 6.PMID: 19808911 [PubMed - indexed for MEDLINE]Free ArticleRelated citations

Pioglitazone reduces monocyte activation in type 2 diabetes.

Pitocco D, Giubilato S, Zaccardi F, Di Stasio E, Buffon A, Biasucci LM, Liuzzo G, Crea F, Ghirlanda G.

Acta Diabetol. 2009 Mar;46(1):75-7. Epub 2008 Sep 27.PMID: 18820825 [PubMed - indexed for MEDLINE]Related citations